Earnings call transcript Q2 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the Brainstorm Cell Therapeutics Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

As a reminder this call is being recorded.

And I'd now like to introduce your host for today's call, Mr. Michael Wood of LifeSci Advisors. Mr. begin. may you Wood,

Michael Wood

corporate thank issued joining its a second including for and Earlier financial this today, the a XXXX, of Brainstorm press quarter you morning us for morning. results update. Good release with

the resources sufficiency market continuing the collaborations Before strategic statements contain I’d as the of that to for remarks, trials such for potential development potential like efforts. Therapeutics ALS, descriptions, statements, the to business company's of over partnerships regarding forecasts clinical and and and passing and and call in company's neuron its regarding beyond, remind future will ability and of existing and Brainstorm to neuron business to Cell it treatment conference company capital neurodegenerative prepared the platform, planning clinical clinical of this the for develop numerous listeners XXXX technology support effectiveness performance, and operations operations the projections its related safety programs, diseases

are from Forward-looking may projected described which any including uncertainties and subject many materially company's results call filings. those today's statements. the company the differ obligation and no to risks The Brainstorm's publicly of from and are SEC company's beyond uncertainties, in on control, statements undertakes forward-looking the time-to-time numerous risks to update

Chief Dr. the this Officer. Brainstorm; Executive on Lindborg, Stacy Lebovits, Patlis, Financial of morning call CEO Co-Chief Interim us and President Joining will be and Chaim Officer; Alla

Executive on questions available your Brainstorm’s addition Chief to Officer, be the session. also the In and will is Q&A during Medical and Kirk Dr. VP call Taylor answer

go ahead. now call the Mr. turn Please to Lebovits. like I'd So to

Chaim Lebovits

joined financial QX progress. and you, Thank results have us discuss to our all XXXX Thank Michael. you recent who

and right to for our make make advisory available priorities to NurOwn to are for ALS sure patients. the for the main NurOwn, forthcoming treatment company the prepared prepare of now is Our investigational therapy committee to

to Advisory and for review Cellular As June, a meeting the September of XX. Therapies convene in Gene NurOwn announced on will Committee Tissue our the FDA BLA

provide which December perspective ALS. for X, have will discuss therapy any assigned clinical supporting have the NurOwn’s upcoming FDA, BLA that patient is the includes filed then been a presentations The addition, as ALS on to be people advocacy unique medical we Other regulatory and In be to of NurOwn’s agenda has the as previously, guided will statisticians will team XXXX. action subject safety, of clinical independent by as by the needs it BLA. our own will same other allow investigational data as NurOwn’s stakeholders, ADCOM detailed living key advocates agency their process, and therapy. including set, of with date is that and as an experts, a an opportunity BrainStorm PDUFA the the evidence, unmet well mentioned

a decision then ADCOM the the for question at X the forth the opportunity will coming the the FDA. on vote vote votes, by as response this advisement have take of be to on set when BLA, preceding agency under will results Members of to the the well meeting by discussions will PDUFA to as which these date. the the The December

available outcome the ensure we on later confident possible, quickly to to make as success Given to this ADCOM generated if remain in the for as have from clinical preparing our a we we approved patients are of NurOwn, achieve strength ability and year. successful can evidence NurOwn the

and that might ago These to we all with being focused ADCOM advance today Our present fully our began raise. expert upcoming the members work as respond we months continue team FDA the and can consultants to preparations is of prepared questions in on ensure ADCOM. and

is taking its and recognize seriously. We that for review the application throughout are FDA agency cooperation grateful to the process very the our

over my call Stacy? the Lindborg, to Dr. turn additional colleague, Stacy now for comments. I'll

Stacy Lindborg

you, Thank Chaim.

are looking FDA regulatory understood. scientific this NurOwn’s apply given overstate cannot meeting We a shown and importance the of and has to rightly to ADCOM in be September need path The when to the last ADCOM. year. willingness NurOwn’s to public in policy the set forward issues offered of ALS the And context flexibility in in therapies the for having therapies by investigational we evaluating over forward need ALS regulatory new the discussed data look forum full an that the

that we NurOwn a to results scientific and support research efficacy includes clinical towards to safety. the which have program. and of in our regulatory data and move continue FDA's decision, full we strongly results NurOwn's comprehensive to remain the process, As clinical confidence our continuing confirm the analysis We the committed believe of

committed also NurOwn. and ongoing effectiveness the learning remain of the safety clinical We to about

reason, to the this ADCOM. goals, we've gather look to elements assembled input For confirmatory committee trial. prior steering providing a design and We to of the the core an forward on update

new Research be Gordon XXXX Related to at continue important ALS biomarker We featuring community scientific recent active conferences. A-List Conference diseases. an the with presentation at We Motor and Neuron data delivered the for

using with As ALS we've examined biomarker neurodegeneration described trial CSF conducted providing NurOwn data a light, importance the evidence Conference This study of neuroprotection. in robust I'll broadly and known rationale And biomarkers of provide pathology, analysis from disease the in and the addition we neuroinflammation, features new trial, neurofilament all study to more fluid three most biomarker biomarker analysis X Gordon of the spanning is collected the during baseline people previously, which of ALS. the CSF data, characteristics participants for. the as in Phase pathways presented living at important

trial. relative that an you're in is The of trial. to in as ALS in the practice of characteristics which co-variants a goal heterogeneous common disease how include a data, analysis we of clinical include information our so Phase we X also this, effects did addition believe influence appropriate I could the in prognosis that appreciate disease. Because to is treatment all is it conclusions to drawing therapy to ALS individual's

well ALS on goal these products. We These Phase biologic characteristics by decided co-variant’s for the of literature. time data five X. efficacy model which disease biomarker trials our use in clinical the importance in adjusting XXXX in include fight exploring to baseline in FDA of and in disease to biomarker symptom the of literature prespecified co-variants, co-variant’s of on released our are final of onset What's trial. primary guidance used that we score co-variants onset When baseline the and were decline, include the the the since for we and release randomized ALS treatment employed in all, as drugs from and rate A-List analyses, and the supported disease ALSFRS-R drill the

in more adds had a poster our across to all biomarker heterogeneity all clinical the baseline analysis data when impact biomarkers for the outcomes. reflect precision on results. these data analysis in disease the co-variants addition As biomarker to the five participants. presentation, Including accounting effect accurately of in treatment simply the can significant highlighted Therefore, coverage

exponential the developers attention of recent biomarkers In years. of lot longitudinal as growth the trial. and NurOwn, treatment the in compared poster, to of placebo community highlighted Neurofilament with publications participants in and a the four we improvements all neurofilament evidenced observed across including biomarkers, been in drug has trajectory in examples light with by getting scientific following the as light the

treatment of participants, decrease P an and neurofilament X.XX. treated around a baseline with significant of in we less week difference placebo to XX% a from X% light than XX observed a NurOwn change In with

in differences also in large Galectin-X. highlighted in MCP-X biomarkers decreases other VEGF and neuroprotective with pro-inflammatory showed The poster and the significant increases biomarker biomarkers, treatment

results also I the presented in two of poster. the

diseases, The hypertension we literature this class decline multiple triple progression. trials, ALS such appear baseline review neurofilament ALSFRS-R. by be light levels promising through of by disease results used presented by baseline of from the and XX approval the neurofilament ALS products to the This ALS addition field. had been week FDA analysis prognostic confirms the last as and for with is greater arterial pulmonary Tofersen. in as baseline This refractory higher to has of values review finding and which other to and in in First, that participants myeloma means motivated the seen was measured light and

is ALS. the of and felt analyses as our into data have targeting derived were between from mechanism the simultaneously understand conduct NurOwn's clinical to neurofilament light to important different while broad relationship a very of We on based And action insights biological these action with associated outcomes. multimodal mechanism we person, deficiencies and

alone inference, ALSFRS-R the called outcome used by with light disease. in decline the The in the have are week change reductions from presented referred and NurOwn the expected to ALSFRS-R to as natural observed in to change that neurofilament regression. it causal And less an progression the due due driven allows analysis in of XX. change us sometimes baseline confirm with we associated NurOwn between approach the analysis would adjusting to light relationship The outcomes explore the the neurofilament to

from reductions in the and literature in benefit driven precedent data set X that trial, neurofilament this reasonably be believe are the Phase given likely to these was We treatment in light support results together, clinical associated hypothesis with ALS. timely are the NurOwn regulatory that Taken the ALS year.

be of accelerated granted ALS. of on which reductions was Biogen approximately and levels decision Ionis light SODX of benefit The ALS associated clinical are the to in person's view Establishing FDA based to to neurofilament treat ability to in light. the that ALS, to person part as X% a form approval likely April, plasma In represents in lower known neurofilament ALS, reasonably with drug genetic patients. approval

voted when ADCOM first was reasonably The based ALS data. reduction predict time committee neurofilament This asked Specifically, biomarker that evidence is the the clinical concentration on supported available the the in approved by likely FDA person the to to was plasma reviewed whether zero. was benefit. nine unanimously to an drug

I'll back for the Chaim some now additional call comments. to turn

Chaim Lebovits

Stacy. you, Thank

earlier payers. patients to who mentioned make approved. manufacturing, on across medical various treat These second NurOwn with physicians, engage main commercial available ALS early and in discussions to is as if we activities affairs with complete commercial priority, to ensure execute that the activities need also include Our and the to order and I preparedness to

NurOwn marrow delivered to be is to to our undergo We're in would then facility, first step series the patients, a this In discussions is shipped from patients the able create where of MSCs therapeutic currently bone to be steps ALS actually manufacturing product. and marrow the initiate would will a then terms of to to how person's each centers. contracts XX personalized from bone the excellence sign We’ll to United set States, manufacturing centers be patients broader they with we of and up collect more for and the begin process centers move so to treatment. can with eight to engagement with that across collect

to the expand so if that As we’re we're to our a of team have capability be approval We before, preparation move in growth. in successful for families as in targeted quickly, process and want will outlined infrastructure wait the in anticipated management build to we to place able We've number achieving possible. hires a XXXX. NurOwn, for as have patients access made we will of far and gain be in so the for and changes short

beginning the with the Dr. function promoted the year, and medical Stacy second Officer. Lindborg Co-CEO. was Chief commercialization to product Kirk efforts, and Vice medical the lead Kirk Then will launch of appointed activities, early Executive Taylor post-approval launches, Medical as we Dr. including in and quarter, President relationships At affairs community. the global planned deepening

advancement expertise in He in approval towards and LabCorp/Covance. and He More the trials. and Development strategy diseases, development neurological brings NurOwn the Dagher, career appointed development plans of Sanofi/Genzyme, rare expansion GSK Executive diseases. and the Chief positions at in XX-years and Vice including Bob approval, July, and as regulatory approximately new such of will first-in-human President of Medicine has leadership began be treatment recently, Bob responsible Officer. industry challenging of we as preclinical at of for translation of into the into and Science Dr. companies for portfolio his research and served clinical

appointment Finally, organizations CFO addition Governance of billion a and annual brings and of has the board Chairman an the with biotech, up the $X spend. important over background as of our a Naor in as we Audit billion includes to Committee and board Compensation XX-years member to Elimination the also with Member made and leader. and Nir Nir experience $X.X has large Finance sales and He pharma overseen in broad and a that work global Senior Committee. of

our This Brainstorm team prepare NurOwn excitement expand other and to to and individuals, focused know prospects. ahead. and fully excited these they exciting future share the vision are talented with I our expanded for around We is team

Alla? Alla the I'll now turn over financials. call our discuss to

Alla Patlis

the XXXX, as Chaim. end quarter, offering. approximately approximately short-term the deposits you, subsequent Thank the bank $X.XX July, XXXX, direct Cash, equivalents proceeds the of and to of end the registered December million net compared at end $X approximately as cash of of In at June in company million the XXXX. $X to were raised

$X.X three XXXX million XXXX the ended $X.X million for three $X.X were the expenses approximately June General respectively. and and million June expenses XX, and XXXX months and XXXX development approximately respectively. for months ended administrative and Research XX, were and $X.X million

approximately per loss ended as million Net months XX, XXXX. the XXXX share XX, for June or of net compared approximately to $X.X for a share, three million or $X.XX was $X.XX June months $X per loss three the ended

Chaim? I'll it turn to back Chaim.

Chaim Lebovits

Thank Alla. from you, read we ask have questions, I’ll from investors. LifeSci the Michael received Wood to Michael?

Michael Wood

Chaim. Thanks,

specifically question accelerated The approval? seeking the is or NurOwn full first approval BLA submitted for

Chaim Lebovits

The Thank approval. is BLA filed you. full seeking

Michael Wood

from been Israeli the Thanks. collected HE And that data the Access treated does patients from the BLA have Program include pathway? under and Expanded

Chaim Lebovits

BLA. the Yes. programs correct. Data included in both That is from were

Michael Wood

biomarker to publish still you Do manuscript? intend your

Chaim Lebovits

compelling strong evidence, part Dr. at of the the our Merit and journal. is data and the and leading Bob papers the Oh, regarded of scientists. Brown support confirm are on a absolutely. senior a and the review clinical researchers paper all That biomarker the Dr. we provides includes The which authors highly data can Cudkowicz

Michael Wood

Thanks.

Gordon this to of is, explain remarks. patients additional listened the And precision means? did the look intrigued to baseline substantially her once at an decide the discussion and make and please Why then characteristics? that Stacy this morning, you recently at to Stacy's presentation that counted you've having So add, going question I prepared to by what did Conference. question, And you change this the next characteristics Gordon? did have results relates baseline the word you Can I'm we're that only

Chaim Lebovits

question. you answer this have I'll Stacy,

Stacy Lindborg

Okay.

emerging to now? for of So the baseline Basically, an why first question, adjust characteristics science. example this is

co-variants disease my actually spoke public And lot from look analyzing the this did tofersen that to ADCOM, of we work documents they did of all baseline a co-variants I the see importance prespecified about exploring as remarks. of including you were efficacy in the in that disease If the analyses tofersen at you'll our data. they FDA that prepared

earlier, perspective. referenced and was FDA final Also, the clinical adjusting provided a co-variants I very for which randomized as timely issued guidance in trials, on important

In us we co-variant, reviewed covered the to on it's stood guidance, prospectively baseline prognostic sponsors focused analysis. that when specify adjusted which what was fact, should out

guideline X adjustment were logical analysis also Therefore, even it and with statistical the our if we acceptable thought associated plan. that use to noted Phase co-variant strongly co-variant specified other. co-variant The was each baseline

of with the these FDA combined data. on co-variant person's importance us guidance, in to co-variant into this led So placed review explore these the our importance

an FDA our note, cases also data and As the in robust. side a done, this the that it's the we health that ran, data, was model quite used tofersen where across significant with we analysis used

your -- understood end. I if the at question Michael, the

by me meant You statement let wanted word to know the precision, I what made first I earlier. the recall

reflect baseline patients. the the in account that of we referenced more we can when accurately data, or I our So treatment analysis heterogeneity of biomarker effect

identify characteristics, treatment. it adding the to by words, is disease these patients, other brings ways which of estimate the precision in So variable that across really help

you're So what co-variant I we're ignoring ability data. that in I this, to is in significance here it. important better This of have disease tell the way influence rate of us precision, analyze in these influence with right And when the the capture is Otherwise, the to And this analysis. mean disease model the co-variant variability progression. the can use will these that the observed co-variant a information included data.

two -- was co-variants models biomarker. model significant effect. that There biomarker trending of The HGF. were had versus the from part results model a did conclusions was are similar no treatment the already that on from the other compared changing both model across actually results that neuroprotective last light, were question how towards the the The the One baseline substantially neurofilament for with biomarkers any very was biomarker not.

biomarkers, for arms the accounting change the in estimate of these important the clinical below the the that both into just in disease as didn't p-value The very had baseline But as the even that influence take percent is because to treatment it two in level information for in resulted well dropping these from account of similar outcomes And characteristics precision the model for more treatment adjust to treatment. addition the pattern could terms. the X.XX. just results overall effect, conventional effect also

Michael Wood

Stacy. Thanks,

Next question, do you intend to a clinical proceed confirmatory with trial?

Chaim Lebovits

Yes.

We Regenerative committee, FDA. the We have have I a confirmatory statisticians. we you you. clinicians in definite reached would be us out a for this and submit months now share intend asked plans California interested thankful and that really such to get with Serum to that It's for share they input us with for from the proceed the Institution trial. would like leading we're application trial. steering Medicine they Thank more we for after to And we there meeting been that know, regard, to that

Michael Wood

different Is or this do granted ADCOM? there that you're the the drugs, you from sign Biogen in a that ADCOM and good reviewed reason bad a amyloid being oversaw you're is that think different ADCOM, a

Chaim Lebovits

Yes.

stem the application to Research, Center to So an cell review was application Drug the and and as Evaluation CDER, [Indiscernible] product that center were that by Evaluation biological filed being advises NDA for submitted Biologics committee application FDA for center biologic with under specific FDA drug the a while of is CBER new a or product, Center Relyvrio submitted advisory as the applications NurOwn both or for and a designation is the the of the license Research. determined

regulation look between in the Inter ADCOMs, be a CBER anyone the Center NurOwn called and therapy's drugs for committee. require two deeper CBERs, document of centers. will biological characteristics Agreement gene product the describes of assigned as a that products advisory and review combination CDER will tissue, to to and is effort this it each to four. has and biological medical those has the and center drug CBER, products and for center a indications example, or reviewed jurisdiction cellular Each by by If collaborative interested multiple

Michael Wood

able submit the by RTF if next or so, relates clinical anticipate amendments CMC The Have on you any initial or been manufacturing to to FDA And letter? do if address their question impact you date? identified controls Thanks. in the PDUFA CMC. not, to the items

Chaim Lebovits

definitely. yes, So

we confirm Sure. amendments amendments. As have and this us to those you. FDA has I'll shared have and submitted again, we allowed the submit Thank

Michael Wood

And, conversations under the been review? the with been has directly any have FDA? While BLA you having

Chaim Lebovits

Yes.

typical is quite accruing we which information, under a responded for We review, we As the received with BLA few have regularly have timely FDA. interactions fashion. for in a requests a to

were able to presentations also interactions. to other share in addition We

Michael Wood

that patients these because Phase the a be patients items XX%. could XX% reported in decline in And below You measured, the study your zero. value not reached had around of X baseline for

you You referred on effect. data to this this these any have please as the expand you effect? biomarker floor do floor for And participants? Can

Chaim Lebovits

Thank you. Stacy, please?

Stacy Lindborg

the for to that as measuring were ALSFRS-R today. bounded Fine of items limitations. reflecting once I the domains scale, the with zero effect like measure of start group therefore to measure account about on in across decline problematic, specifically zero. it ability effect XX% any rate But is and in just values, by the further Motor at reach Motor And there trial, the Gross decline, that outcome expected Sure. the in half in trials. bottom that observed This can't zero The we a and a XX% all question, because on treatment this in in starting fact has the and want Fine best a treatment about have asked the ALSFRS-R remains with the at show Fine Motor participants items, ALSFRS-R started who high of approximately the items. especially subdomain confounds a rate the six that was the participants zero Gross Gross of of scale,

So it's biomarker data question a these about in participants.

biomarker data participants. looked have at We in these

in in what was includes NurOwn improvements ALSFRS-R. in was population Gordon neuroinflammation, remarks, the on baseline at challenges. pathways observed that and with that similar to that studied placebo fact, that the scores treatment and neurodegeneration disease the three this is in ALS reported ALS demonstrated fact, below in We, neuroprotection. the participants opening trial, important in active, patterns participants first, the biomarkers important which scale, versus see and XX we very participants, my with this In overall I measurement we referenced where all significant with and trial suggests across biologically NurOwn advanced ALSFRS-R the And scale is Conference

Michael Wood

Thanks, Stacy.

said relates the that product to some this Next years, please about to on other provide Investors with hearing working have use it's of it now question your specificity for clinical on for BrainStorm its indications. has what working been respect pipeline. means.

Chaim Lebovits

this Dr. I'll Kirk take thank ask Oh, question, please? Taylor you. to

Kirk Taylor

a Great, and a results Chaim. treatment announced we you Sure. NurOwn positive progressive study Well, completed Thank Phase MS evaluating in X for as XXXX.

neurologists expertise prepared remains with the worked the have study. the amyloid impact consulting on in deep a the Alzheimer's need protocol concept to design a remove unmet statisticians of NurOwn the with trial Alzheimer's We've to disease. have builds context next that NurOwn and concept with designed the in MS and and prepared leading solid with Xa experts in that plaque, that We also protocol Phase study that's of treatments in disease approval of completed

removed, function view NurOwn's question disease. it above in baseline action mechanism [Indiscernible] addressed levels. the here cognitive applications patients supports could been though, for amyloid our in increased have of to the neurodegenerative may NurOwn question. that Design broad is That's

However…

Michael Wood

Kirk?

Kirk Taylor

this At and resources in primarily we programs point, are and we focused intend approval We ALS and you. sorry, focus however, getting indication. that the forward patients allow. could to move those as on with of many stakeholders. Thank biotech the other benefit our program near-term like create I'm for programs in resources to industry, potentially need our prioritize that peers in value

Chaim Lebovits

Thank you.

Michael Wood

final one offering on with the Maxim BrainStorm $X.X million? follow-on question. Did finalize have I for

Chaim Lebovits

Yes.

this as we on publish practice, to a X-K. an the addition matter, did common In PR

we'll we our Michael? finance favorable that opportunistic most of the way be some on this, options at for the comes to finance, have going will utilize company need. multiple time quite Just the And ways explore color opportunities provide to continue will more to forward. to best the

Michael Wood

final That's the question.

Chaim Lebovits

Thank you any would open much. so Jenny, questions? for additional you

Operator

problem. At floor Your are opening first is Maxim your time, Yes. from McCarthy, is question [Operator Jason coming the line we No Group. live. Instructions] Jason this for questions.

Jason McCarthy

the there Thanks all. co-variant in on your to about there to same the particularly forward that a no you presentation for in do that September. analysis a NFL July, confirmatory that what co-variant Really the was do vote but looking the Hi, where you the you've and questions study. full expect shown Biogen expect And gotten of based X, had around taking ADCOM differences ADCOM, you was question? questions. requiring in some on three in expect, NFL, I on X similar guess, voting, the approval, three Do yes, that

Chaim Lebovits

very Thank you Stacy? much.

Stacy Lindborg

Yes. very Hi, ADCOM, [Indiscernible] My different center. it's a mechanism FDA you. from different different is to of action. about a that thinking this is applications, Different hear Jason.

I presenting quite think is the of different. each what drug is programs evidence was also there

not but for right the time assume the of very the to ADCOM. regulators, actually were light think our close in -- to association we'll the were know the interesting And light mention the we'll course ability the and clinical questions with association show neurofilament questions that before results relevant, a get in to actually learned career my neurofilament So insights and improved is of strength. outcomes bring an we into I've the But related are reductions anything over with the both questions the certain asked what with I that to ADCOM. regard

Jason Mccarthy

including that point more or the part a than and presentation, drug? safety ALS, therapy, on as of be is genetically approach made ADCOM other Biogen a it NurOwn, is of an will drugs safer it the of then far that the manipulated apparently aspects autologous cell not given it's During

Chaim Lebovits

Stacy?

Stacy Lindborg

Yes.

set and NurOwn, generated, full but efficacy our Jason, share of and a safety as will the in result your present compelling all the overview safety way of data, the made of will in provide product confidence we've data a we the is presentation. that at we only data our and we So of not

Jason Mccarthy

you or plan a $XXX,XXX north I it's but pricing that the Is but for from to around on pricing -- a mentioned perspective, cell all that to complete told a plan? lastly, launch from need that similar marrow bone year. your question had getting initial strategy per sales right How to large centers you possibly of commercialization for know eight [Indiscernible] And a And just collection. early, commercialization treatment, about force Chaim, therapy? could $XX,XXX brief it's a would of just XX initially potential expect perspective for at a just you from a so,

Chaim Lebovits

Yes.

So very much. thank you

[Indiscernible] injections, we'll be that's of more that the not only these focusing. And think will of know it's these questions, helps marrow intrathecal out. many know. bone answer very really where aspirations, doing as regulatory excellence, and the but And you're to things some for You treatments of expertise. some laying the is [Indiscernible] find like But treatment which reasons, that out for us you I premature I centers what be important more and to centers have

make centers to where many lot center have nearby probably the with geographies to also close are. talking from And of we're centers, the other experience product, patients our already other trial, start a but that sure with of a which will they have geographical

previous though show significant to that answered repeat we believe that and our data to you comment a a forward, data body asked once did time, question of will dive little clinical we of Stacy a of the statistical course, and Just you not we significance, a hit evidence think is, primary set, the bit even we're show spent into want the into for more you. don't statistically to which are lot set, it I able deeper and results bring able to endpoint

clinical see we're will it's part we on of clinical, what why more But support to you're able the But secondary the be seeing the that -- even focused endpoints, gives for I score, eliminate think in biomarker for covers advanced significant strong it and more as patients. question and sent therefore, when in statistical data advanced where the to both patients, primary results. not we the the the think

for not lay to Of questions, those But what That's it very the we're thank much going at to out here. course, ADCOM. going do you Jason. we're

Jason McCarthy

Chaim and you. thank Stacy,

Chaim Lebovits

Sure.

Operator

we much. can further Thank queue. you for appear hand questions have closing to okay, [Operator any I very in the back over It’s Instructions] don't comments.

Chaim Lebovits

really like looks that. is job you. a did Thank plan, out I there the laying and appreciate wonderful Stacy It additional no questions.

-- let's call had morning. this So we long a

listening back in thank Back get the very to listening you. to again, to plan thank and much, of investors August want our again Jenny. in everyone let's you importance shows listening. for to really listening our August to in, so many So for forward, the you -- have we it mid of time We today. to investors you Thank

Operator

Thank you, today's Chaim. conclude call. conference This does

may your you time, phone participation. day. have for disconnect You a wonderful this at lines and your Thank

Brainstorm Cell Therapeutics (BCLI) 14 Aug 232023 Q2 Earnings call transcript